The U.S. Food and Drug Administration approved ensitrelvir fumaric acid — marketed as Xocova by Shionogi — on 1 June 2026, making it the first and only oral antiviral medication approved in the United States specifically for the prevention of COVID-19 in individuals who have had recent close contact with an infected person.
The approval is significant for what it represents as much as for what it does clinically. Since Pfizer’s nirmatrelvir-ritonavir (Paxlovid) was authorised in late 2021 for treatment of mild-to-moderate COVID-19, the 3CL protease inhibitor class has become a cornerstone of antiviral management in immunocompromised and high-risk populations. Ensitrelvir extends that class into a new indication: post-exposure prophylaxis, or PEP, where the goal is to prevent infection from becoming symptomatic disease in individuals already exposed but not yet testing positive.
The mechanism of action is conserved across the 3CL inhibitor class. SARS-CoV-2 relies on its main protease, 3CLpro, to cleave the viral polyprotein into functional replication machinery. Ensitrelvir binds covalently to the catalytic cysteine of 3CLpro, blocking this cleavage and halting viral replication before the virus can establish productive infection in the upper respiratory tract.
What distinguishes ensitrelvir from nirmatrelvir in the PEP context is its pharmacokinetic profile. Ensitrelvir does not require co-administration with ritonavir — the pharmacokinetic booster needed to maintain nirmatrelvir plasma concentrations, which introduces drug-drug interaction complexity. Ensitrelvir achieves its target plasma levels as a standalone once-daily tablet, simplifying the post-exposure management workflow considerably.
The FDA’s approval was based on data from Shionogi’s Phase 3 STRIVE-PEP trial, which evaluated a five-day course of ensitrelvir 125 mg once daily versus placebo in household contacts of confirmed COVID-19 cases, initiated within 72 hours of exposure. The trial met its primary endpoint of virologically confirmed COVID-19 in the 14 days following exposure, with a statistically significant reduction in the proportion of participants who developed symptomatic, confirmed disease.
Secondary endpoints, including time to first positive antigen test and peak viral load, also favoured ensitrelvir. The tolerability profile was consistent with prior ensitrelvir treatment studies — the most common adverse events were headache and skin discolouration, the latter a class effect of 3CL protease inhibition that had been characterised in earlier treatment trials.
The approved indication targets adult and adolescent patients aged 12 and older who are at risk of severe COVID-19 outcomes — a population that encompasses the immunocompromised, elderly, and those with cardiovascular or metabolic comorbidities.
Shionogi has indicated it is engaged in supply and distribution discussions with national health authorities internationally, though no ex-US approvals have been announced. The TGA in Australia has not yet indicated a review timeline for Xocova.
